150 related articles for article (PubMed ID: 35850243)
1. Long non-coding RNA ANRIL promotes chemoresistance in triple-negative breast cancer via enhancing aerobic glycolysis.
Ma J; Zhao W; Zhang H; Chu Z; Liu H; Fang X; Tang D
Life Sci; 2022 Oct; 306():120810. PubMed ID: 35850243
[TBL] [Abstract][Full Text] [Related]
2. Long non-coding RNA ANRIL promotes carcinogenesis via sponging miR-199a in triple-negative breast cancer.
Xu ST; Xu JH; Zheng ZR; Zhao QQ; Zeng XS; Cheng SX; Liang YH; Hu QF
Biomed Pharmacother; 2017 Dec; 96():14-21. PubMed ID: 28961506
[TBL] [Abstract][Full Text] [Related]
3. Knockdown of LncRNA-UCA1 suppresses chemoresistance of pediatric AML by inhibiting glycolysis through the microRNA-125a/hexokinase 2 pathway.
Zhang Y; Liu Y; Xu X
J Cell Biochem; 2018 Jul; 119(7):6296-6308. PubMed ID: 29663500
[TBL] [Abstract][Full Text] [Related]
4. Downregulation of lncRNA ANRIL inhibits proliferation, induces apoptosis, and enhances radiosensitivity in nasopharyngeal carcinoma cells through regulating miR-125a.
Hu X; Jiang H; Jiang X
Cancer Biol Ther; 2017 May; 18(5):331-338. PubMed ID: 28402230
[TBL] [Abstract][Full Text] [Related]
5. Long non-coding RNA NEAT1 confers oncogenic role in triple-negative breast cancer through modulating chemoresistance and cancer stemness.
Shin VY; Chen J; Cheuk IW; Siu MT; Ho CW; Wang X; Jin H; Kwong A
Cell Death Dis; 2019 Mar; 10(4):270. PubMed ID: 30894512
[TBL] [Abstract][Full Text] [Related]
6. Effect of lncRNA ANRIL knockdown on proliferation and cisplatin chemoresistance of osteosarcoma cells in vitro.
Li G; Zhu Y
Pathol Res Pract; 2019 May; 215(5):931-938. PubMed ID: 30777616
[TBL] [Abstract][Full Text] [Related]
7. Long non-coding RNA ANRIL knockdown suppresses apoptosis and pro-inflammatory cytokines while enhancing neurite outgrowth via binding microRNA-125a in a cellular model of Alzheimer's disease.
Zhou B; Li L; Qiu X; Wu J; Xu L; Shao W
Mol Med Rep; 2020 Aug; 22(2):1489-1497. PubMed ID: 32626959
[TBL] [Abstract][Full Text] [Related]
8. LncRNA DANCR upregulation induced by TUFT1 promotes malignant progression in triple negative breast cancer via miR-874-3p-SOX2 axis.
Wu G; Zhou H; Li D; Zhi Y; Liu Y; Li J; Wang F
Exp Cell Res; 2020 Nov; 396(2):112331. PubMed ID: 33058834
[TBL] [Abstract][Full Text] [Related]
9. CircWHSC1 regulates malignancy and glycolysis by the miR-212-5p/AKT3 pathway in triple-negative breast cancer.
Ding L; Xie Z
Exp Mol Pathol; 2021 Dec; 123():104704. PubMed ID: 34624276
[TBL] [Abstract][Full Text] [Related]
10. Long non-coding RNA ANRIL and its target microRNAs (microRNA-34a, microRNA-125a and microRNA-186) relate to risk stratification and prognosis in multiple myeloma.
Yin Y; Yang W; Zhang L; Liu K; Luo Z
Hematology; 2021 Dec; 26(1):160-169. PubMed ID: 33528317
[TBL] [Abstract][Full Text] [Related]
11. Long non-coding RNA TUG1 sponges miR-197 to enhance cisplatin sensitivity in triple negative breast cancer.
Tang T; Cheng Y; She Q; Jiang Y; Chen Y; Yang W; Li Y
Biomed Pharmacother; 2018 Nov; 107():338-346. PubMed ID: 30098551
[TBL] [Abstract][Full Text] [Related]
12. Formononetin relieves the facilitating effect of lncRNA AFAP1-AS1-miR-195/miR-545 axis on progression and chemo-resistance of triple-negative breast cancer.
Wu J; Xu W; Ma L; Sheng J; Ye M; Chen H; Zhang Y; Wang B; Liao M; Meng T; Zhou Y; Chen H
Aging (Albany NY); 2021 Jul; 13(14):18191-18222. PubMed ID: 34289449
[TBL] [Abstract][Full Text] [Related]
13. Knockdown of lncRNA ANRIL inhibits the development of cisplatin resistance by upregulating miR‑98 in lung cancer cells.
Wang X; Zhang G; Cheng Z; Dai L; Jia L; Jing X; Wang H; Zhang R; Liu M; Jiang T; Yang Y; Yang M
Oncol Rep; 2020 Sep; 44(3):1025-1036. PubMed ID: 32705261
[TBL] [Abstract][Full Text] [Related]
14. LncRNA HCP5 promotes triple negative breast cancer progression as a ceRNA to regulate BIRC3 by sponging miR-219a-5p.
Wang L; Luan T; Zhou S; Lin J; Yang Y; Liu W; Tong X; Jiang W
Cancer Med; 2019 Aug; 8(9):4389-4403. PubMed ID: 31215169
[TBL] [Abstract][Full Text] [Related]
15. Long non-coding RNA SNHG8 enhances triple-negative breast cancer cell proliferation and migration by regulating the miR-335-5p/PYGO2 axis.
Qian J; Lei X; Sun Y; Zheng L; Li J; Zhang S; Zhang L; Li W; Shi J; Jia W; Tang T
Biol Direct; 2021 Aug; 16(1):13. PubMed ID: 34362407
[TBL] [Abstract][Full Text] [Related]
16. LncRNA ANRIL promotes HR repair through regulating PARP1 expression by sponging miR-7-5p in lung cancer.
Du Z; Zhang F; Liu L; Shen H; Liu T; Jin J; Yu N; Wan Z; Wang H; Hu X; Chen Y; Cai J
BMC Cancer; 2023 Feb; 23(1):130. PubMed ID: 36755223
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-125a attenuates the chemoresistance against ubenimex in non-small cell lung carcinoma via targeting the aminopeptidase N signaling pathway.
Li C; Zhai W; Wan L; Li J; Huang A; Xing S; Fan K
J Cell Biochem; 2020 Feb; 121(2):1716-1727. PubMed ID: 31595566
[TBL] [Abstract][Full Text] [Related]
18. Long non-coding RNA MALAT1 promotes proliferation and invasion via targeting miR-129-5p in triple-negative breast cancer.
Zuo Y; Li Y; Zhou Z; Ma M; Fu K
Biomed Pharmacother; 2017 Nov; 95():922-928. PubMed ID: 28915533
[TBL] [Abstract][Full Text] [Related]
19. Knockdown of ANRIL aggravates H
Li R; Yin F; Guo YY; Zhao KC; Ruan Q; Qi YM
Biomed Pharmacother; 2017 Aug; 92():952-961. PubMed ID: 28609843
[TBL] [Abstract][Full Text] [Related]
20. lncRNA GAS5-promoted apoptosis in triple-negative breast cancer by targeting miR-378a-5p/SUFU signaling.
Zheng S; Li M; Miao K; Xu H
J Cell Biochem; 2020 Mar; 121(3):2225-2235. PubMed ID: 31692053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
